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High-grade glioma (HGG) is highly angiogenic, but antiangiogenic therapy has transient clinical benefit in only a fraction of 
patients. Vascular regulators of these heterogeneous responses remain undetermined. We found up-regulation of Sox7 and 
down-regulation of Sox17 in tumor endothelial cells (tECs) in mouse HGG. Sox7 deletion suppressed VEG FR2 expression, 
vascular abnormality, hypoxia-driven invasion, regulatory T cell infiltration, and tumor growth. Conversely, Sox17 deletion 
exacerbated these phenotypes by up-regulating Sox7 in tECs. Anti-VEG FR2 antibody treatment delayed tumor growth by 
normalizing Sox17-deficient abnormal vessels with high Sox7 levels but promoted it by regressing Sox7-deficient vessels, 
recapitulating variable therapeutic responses to antiangiogenic therapy in HGG patients. Our findings establish that Sox7 
promotes tumor growth via vessel abnormalization, and its level determines the therapeutic outcome of VEG FR2 inhibition 
in HGG. In 189 HGG patients, Sox7 expression was heterogeneous in tumor vessels, and high Sox7 levels correlated with poor 
survival, early recurrence, and impaired vascular function, emphasizing the clinical relevance of Sox7 in HGG.
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Introduction
Although vessel abnormality including tumor angiogenesis is a 
hallmark of cancer, its pattern and underlying mechanisms are 
various, depending on the tumor type (Hanahan and Weinberg, 
2000, 2011; Carmeliet and Jain, 2011). High-grade glioma (HGG) 
is a cancer with prominent vessel abnormality (Jain et al., 2007; 
Takano, 2012; Das and Marsden, 2013). The molecules responsi-
ble for aberrant vessels have been elucidated, and their inhibition 
helps to reduce vessel abnormality in HGG animal models (Reis 
et al., 2012; Park et al., 2016). Although HGG is also character-
ized by angiogenic vessels, tumor angiogenesis is rarely observed 
in available HGG models; rather, tumor cells coopt preexisting 
vessels for growth (Blouw et al., 2003; Bergers and Hanahan, 
2008; Takano, 2012). Because of difficulty in modeling, the 
molecular mechanisms of tumor angiogenesis in HGG remain 
elusive. How tumor angiogenesis is inactive in HGG models also 
remains unclear.
Tumor angiogenesis has been a target of  cancer ther-
apy. Though blockade of VEGF has been effective in treating 
several cancers (Saharinen et al., 2011), its clinical benefit 
is limited in HGG largely as a result of two different tumor 
behaviors: resistance and indifference. The resistance mech-
anisms to anti-VEGF (α-VEGF) therapy have been fairly elu-
cidated: bevacizumab, an α-VEGF antibody (Ab), produces 
initial beneficial effects in a subpopulation of HGG patients, 
but tumors rapidly relapse via alternative angiogenic factors 
(Batchelor et al., 2007; Scholz et al., 2016) and enhanced tumor 
invasion (Pàez-Ribes et al., 2009; Lu et al., 2012). Because of 
this resistance, α-VEGF Ab failed to improve overall survival 
in HGG patients in large-scale clinical studies (Bergers and 
Hanahan, 2008; Chinot et al., 2014; Gilbert et al., 2014). How-
ever, regarding the presence or absence of beneficial outcome, 
HGG patients can be categorized into responder and nonre-
sponder. The responders showed prolonged progression-free 
survival, and the nonresponders failed to show even transient 
therapeutic benefit (Chinot et al., 2014; Gilbert et al., 2014). 
Despite its limited clinical benefit, α-VEGF Ab is still used for 
treating HGG because there are few treatment options. How 
anti-VEGF therapy gives rise to different responses in HGG 
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patients remain to be determined to predict patients suitable 
for anti-VEGF therapies.
To understand the mechanism of the variable response to 
antiangiogenic therapy, we sought to identify angiogenic reg-
ulators in HGG. SoxF transcription factors consisting of Sox7, 
Sox17, and Sox18 are expressed specifically in endothelial cells 
(ECs) and contribute to vascular morphogenesis (Francois 
et al., 2010; Corada et al., 2013; Lee et al., 2014; Zhou et al., 
2015). Sox7 and Sox17 genetically cooperate for developmental 
angiogenesis by reinforcing VEGF signaling (Kim et al., 2016). 
Although the role of Sox17 was found in subcutaneous ectopic 
tumors (Yang et al., 2013), Sox7 has not been studied in the 
context of tumor angiogenesis. In this study, we investigated 
the role of Sox7 and Sox17 in tumor angiogenesis in orthotopic 
mouse HGG models. In an HGG model, Sox7 promoted tumor 
angiogenesis, and Sox17 suppressed it. Sox7 levels in tumor 
vessels correlated with therapeutic efficacy of α-VEG FR2 Ab. 
In a large HGG patient population, Sox7 expression in tumor 
vessels was heterogeneous. High Sox7 levels correlated with 
poor prognosis and abnormal tumor vessels, emphasizing clin-
ical relevance of Sox7 in HGG.
Results
Vascular characterization of murine HGG models
To reveal molecular mechanisms of vascular characteristics of 
HGG, we established a mouse orthotopic glioma model by intra-
cranially injecting GL26l glioma cells into congenic B6 mice. 
GL261-derived glioma recapitulated the malignant character-
istics of HGG (Fig.  1 A) as reported (Kerber et al., 2008). We 
studied the vascular features of GL261-derived HGG. Compared 
with nontumor brain vessels, HGG vessels exhibited twofold 
area, halved number (315/mm2 of normal brain vs. 170/mm2 of 
GL261 HGG), enlarged diameter, and halved branching (Fig. 1, 
B–E), implying that, rather than angiogenesis, regression and 
dilation are the major vascular changes in this tumor model. 
HGG vessels exhibited poor pericyte coverage, hyper-leakage, 
and hypoperfusion (Fig. 1, F–H). Thus, orthotopic GL261 HGG 
is characterized by aberrant vasodilation and impaired vas-
cular function.
To identify the molecular players for vessel abnormality, 
we profiled the endothelial transcriptomics of HGG and brain. 
Two endothelial populations expressed a total 15,111 genes, and 
346 genes were differentially expressed by more than twofold 
(Fig. 1 I). Suppressed Wnt signaling was predicted in tumor ECs 
(tECs; Fig. 1 J) in line with dysregulated endothelial Wnt signal-
ing in brain tumors (Reis et al., 2012; Phoenix et al., 2016). Gene 
ontology analysis showed the greatest changes in the category 
of transcriptional regulation (Fig.  1  K). Notably, angiogenic 
transcription factor Sox7 was up-regulated in tECs (Fig.  1  L), 
suggesting its role in vessel abnormality in HGG. We examined 
Sox7 expression in low-grade glioma and HGG patients. Non-
tumor human brain vessels had no detectable Sox7 expression 
(Fig. 1 M). Although vascular expression of Sox7 was detected in 
a fraction of grade II glioma tissues, its frequency and intensity 
were higher in grade III/IV glioma tissues (Fig. 1, N–O), suggest-
ing clinical relevance of Sox7 expression in HGG.
Opposing expression patterns of Sox7 and 
Sox17 in HGG vessels
We verified vascular Sox7 expression in orthotopic GL261 HGG 
grown in Sox7mCh/+ mice. Consistent with the RNA sequencing 
data, 63% of HGG vessels expressed Sox7-mCherry fluorescence, 
whereas nontumor brain vessels rarely expressed it (Fig. 2 A). 
Because Sox17 is homologous to Sox7 in DNA sequence, we exam-
ined vascular Sox17 expression in GL261 HGG grown in Sox17GFP/+ 
mice. 41% of nontumor brain vessels, but only 15% of HGG ves-
sels, expressed Sox17-GFP fluorescence (Fig. 2 B). Robust Sox7 
expression and decreased Sox17 expression were confirmed 
in HGG vessels from wild-type mice (Fig. S1, A and B) and a 
patient-derived xenograft HGG model (Fig. S1, C and D; Yin et 
al., 2017). In confocal microscopy, 48% of tECs (149 out of 308) 
exhibited Sox7 immunostaining in their nuclei, whereas none of 
∼40 pericytes exhibited Sox7 immunostaining, indicating that 
Sox7 is specifically expressed in the tECs of HGG vessels (Fig. S1 
E). These results reveal different endothelial expression patterns 
for Sox7 and Sox17 in HGG and nontumor brain.
In contrast, Sox17 was previously shown to be highly 
expressed in tumor vessels in a subcutaneous ectopic Lewis lung 
carcinoma (LLC) model (Yang et al., 2013). To clarify the cause of 
different Sox17 expression patterns between these tumor mod-
els, we examined Sox7 and Sox17 expression in tumor vessels by 
injecting GL261 or LLC cells into Sox7mCh/+ and Sox17GFP/+ mice 
either intracranially or subcutaneously. In GL261- and LLC-de-
rived tumors grown in brain, >60% of tumor vessels expressed 
Sox7-mCherry, but only 12–15% of them expressed Sox17-GFP 
(Fig. 2, C and E). However, in GL261- and LLC-derived tumors 
grown subcutaneously, 75–80% of tumor vessels expressed 
both Sox7-mCherry and Sox17-GFP (Fig. 2, D and E). In contrast, 
embryonic and neonatal brain vessels featured by angiogenic 
tip cells robustly expressed both Sox7 and Sox17 (Fig. 2 F). These 
results demonstrate that the expression pattern of Sox7 and 
Sox17 in HGG vessels is controlled by the growth environment 
in the brain rather than the identity of tumor cells and suggest 
that this brain-specific regulation in tumor vessels differs from 
regulation in developing brain vessels.
Given the contrasting vascular expression of Sox7 and Sox17 
in HGG, we examined their expression in individual tumor 
vessels. Sox7 immunostaining was evident in Sox17-GFP–low 
vessels but decreased in Sox17-GFP–high vessels (Fig.  2  G). 
Sox17 immunostaining was rare in Sox7-mCherry–high ves-
sels but prominent in Sox7-mCherry–low vessels (Fig.  2  H). 
These findings indicate an inverse relationship between Sox7 
and Sox17 expression in HGG vessels. Likewise, no coincident 
vascular expression of Sox7 and Sox17 was observed in grade 
III/IV glioma tissues (Fig. 2 I). Compared with Sox7-mCherry–
low or Sox17-GFP–high tumor vessels, Sox7-mCherry–high or 
Sox17-GFP–low tumor vessels had twofold tortuosity, twofold 
branching, and moderately narrow diameters (Fig. S1, F and 
G). Similarly, Sox7-positive tumor vessels had more tortuosity 
and branching and narrow diameters relative to Sox17-pos-
itive tumor vessels in GL261 HGG grown in wild-type mice, 
patient-derived xenograft HGG, and grade III/IV patient glioma 
samples (Fig. S1, I and J). The expression pattern of Sox7 and 
Sox17 being associated with contrasting vascular morphology 
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suggests that Sox7 and Sox17 may regulate vascular morpho-
genesis in an opposing manner in HGG.
We examined Sox7 and Sox17 expression in various tissues. 
Sox17, but not Sox7, was expressed in retina capillaries as in brain 
capillaries (Fig. S1 K), but Sox7 and Sox17 showed coincidental 
expression in the capillaries of gastrointestinal tissues and arter-
ies of the skin (Fig. S1, L–N). Thus, the pattern of Sox7 and Sox17 
expression is contextually heterogeneous in adult vessels.
Sox7 deletion delays HGG growth by attenuating 
vascular abnormality
To reveal the role of Sox7 in HGG vessels, we studied tumor 
progression and tumor vessels by excising floxed Sox7 alleles 
from the ECs of mutant mice, Cdh5-CreERT2;Sox7fl/fl (Sox7iΔEC), 
bearing orthotopic HGG derived from GFP-expressing GL261. 
Sox7 expression was not detectable after tamoxifen adminis-
tration (Fig. S2 A). Mutant mice lacking endothelial Sox7 had 
decreased tumor size 3 wk after implantation (Fig. 3 A), and their 
survival extended (median survival: 33 d in Sox7iΔEC mice vs. 28 
d in controls; Fig. 3 B).
We studied the morphology of Sox7-deficient HGG vessels. As 
mentioned earlier in this paper, HGG vessels in wild-type mice 
had a decreased number and branching, but substantial increase 
in diameter, thereby leading to twofold increased vessel area 
relative to nontumor brain vessels (Fig. 1, B–E). Compared with 
changes in control HGG vessels, Sox7-deficient vessels had less 
of a decline in number, more severe decrease in branching, and a 
modest increase in diameter, resulting in no significant increase 
Figure 1. Abnormal vessels in HGG have distinct endothelial transcripts. (A–H) H&E staining (A) and CD31-positive vessels (B–H) in nontumor brain and 
orthotopic HGG. (B–E) Vascular network (B) and quantification of vessel area (C), vessel number based on vessel diameter (D), and vessel branching (E). (F) 
PDG FRβ-positive pericytes and quantification of coverage. (G) Evans blue (EB) and quantification of extravasation. (H) Lectin and quantification of vascular 
perfusion. Values are presented as mean ± SD (n = 5). **, P < 0.01. (I–L) Transcriptome analyses of normal brain and HGG ECs by RNA sequencing (n = 3). (I–K) 
Heat map (I), top five canonical pathways by the ingenuity pathway analysis (IPA; J), and top five gene ontology (GO) terms in biological processes (K) using 
346 genes differentially expressed by more than twofold (P < 0.05). (L) Heat map of differentially expressed genes in the category of transcriptional regulation. 
(M) No Sox7 but robust Sox17 immunostaining in human nontumor brain vessels. (N and O) Sox7 immunostaining in tumor vessels from glioma patients with 
different grades (N) and intensity scores of nine grade II, six grade III, and nine grade IV patients (O) Bars, 100 µm.
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Figure 2. Sox7 is up-regulated in HGG vessels. (A–H) CD31-positive vessels in Sox7mCh/+ and Sox17GFP/+ mice. (A and B) Sox7-mCherry (A) and Sox17-GFP (B) fluo-
rescence and signal quantification in nontumor brain and tumor vessels of mice bearing orthotopic GL261 HGG. (C and D) Sox7-mCherry and Sox17-GFP fluorescence in 
tumor vessels. GL261- and LLC-derived intracranial (C) and subcutaneous tumors (D). (E) Quantification of fluorescence signals in C and D. (F) Robust Sox7-mCherry and 
Sox17-GFP signals in brain vessels on embryonic day 10.5 (E10.5) and postnatal day 5 (P5). (G) Sox7 immunostaining and its quantification in Sox17-GFP–low and –high 
vessels in GL261 HGG. (H) Sox17 immunostaining and its quantification in Sox7-mCherry–high and –low vessels in GL261 HGG. (I) Sox7 and Sox17 immunostaining in 
tumor vessels using adjacent sections from the same HGG patients. Values are presented as mean ± SD (n = 5). **, P < 0.01. Bars: 100 µm (A–D and G–I); 50 µm (F).
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Figure 3. Sox7 deletion delays HGG growth by reducing vessel abnormality. (A) GL261-GFP HGGs grown in control (Ctrl) and Sox7iΔEC (KO) mice and quan-
tification of tumor volume (n = 10). (B) Survival curves for HGG-bearing mice (n = 10). *, P < 0.05 (log-rank test). (C-I) CD31-positive HGG vessels in control and 
KO mice. (C) Normalized vessel morphology by Sox7 deletion and quantification of vessel area, branching, number, and diameter. (D and E) PDG FRβ-positive 
pericytes (D) and Col4-positive basement membrane (BM; E) and quantification of coverage. (F) Lectin and quantification of vascular perfusion. (G) Ter119-pos-
itive erythrocytes and quantification of hemorrhage. (H) Pimonidazole adduct (hypoxyprobe, HP) and quantification of hypoxic area. (I) Reduced perivascular 
invasion of GL261-GFP tumor cells by Sox7 deletion. (J) Diagrams depicting normal brain vessels and control, Sox7-deficient, and Sox17-deficient HGG vessels. 
Values are presented as mean ± SD (n = 5 unless otherwise denoted). *, P < 0.05; **, P < 0.01; ***, P < 0.001. Bars: 2 mm (A); 100 µm (C–I).
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Figure 4. Sox17 deletion promotes HGG growth by increasing vessel abnormality. (A) GL261-GFP HGGs grown in control (Ctrl) and Sox17iΔEC (KO) mice 
and quantification of tumor volume (n = 10). (B) Survival curves for HGG-bearing mice (n = 10). *, P < 0.05 (log-rank test). (C–K) CD31-positive HGG vessels 
in control and KO mice. (C) Increased vessel abnormality with Sox17 deletion and quantification of vessel area, branching, number, and diameter. (D and E) 
Increased sprouting (D) and appearance of tip cells (arrow) by Sox17 deletion (E). (F and G) PDG FRβ-positive pericytes (F) and Col4-positive basement membrane 
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in vessel area compared with nontumor brain vessels (Fig. 3, C 
and J). Pericytes, basement membrane, and junctional VE-cad-
herin were restored in Sox7-deficient vessels relative to control 
HGG vessels (Fig.  3, D–E; and Fig. S2 B). Increased perfusion, 
decreased leakage, and reduced microhemorrhage were found 
in Sox7-deficient vessels (Fig. 3, F and G; and Fig. S2 C). In line 
with this, Sox7 deletion substantially diminished tumor hypoxia 
(Fig. 3 H). However, Sox7 deletion induced no discernable vessel 
changes in nontumor brain tissues (Fig. S3, A–F). These results 
indicate that Sox7 deletion can rescue the morphology, structure, 
and function of the HGG vascular network.
We explored how Sox7 deletion suppresses tumor growth 
by examining cellular changes in tumor tissues. Sox7 abla-
tion reduced necrosis, apoptosis, and proliferation, which is 
unlikely to explain tumor growth suppression (Fig. S2, D–F). 
Hypoxia is known to trigger tumor invasion. Sox7 ablation 
inhibited tumor invasion at the border (Fig. 3 I and Fig. S2 G). 
These results suggest decreased tumor invasion by the relief 
of hypoxic stress as a cellular mechanism for delayed tumor 
growth by Sox7 deletion.
Sox17 deletion promotes HGG growth by exacerbating 
vascular abnormality
Given the association of Sox17 expression with particular vessel 
morphology, we studied the role of Sox17 in tumor progression 
and tumor vessels by deleting endothelial Sox17 alleles from 
mutant mice, Cdh5-CreERT2;Sox17fl/fl (Sox17iΔEC), bearing orthot-
opic GL261-GFP HGG. Effective Sox17 deletion was confirmed 
by a lack of Sox17 immunostaining in brain arteries (Fig. S2 
H). Compared with controls, mutant mice lacking endothelial 
Sox17 showed increased tumor growth 3 wk after implantation 
(Fig. 4 A) and succumbed to tumor burden earlier (median sur-
vival: 24.5 d in Sox17iΔEC mice vs. 28 d in controls; Fig. 4 B).
Regarding vessel morphology, Sox17-deficient HGG vessels 
exhibited a greater decrease in number but greater increase in 
branching and diameter than control HGG vessels, leading to a 
further 1.8-fold increase in vascular area (Figs. 3 J and 4 C). Inter-
estingly, in contrast to control and Sox7-deficient HGG vessels, 
Sox17-deficient HGG vessels had abundant sprouts (Fig. 4 D) and 
tip cells, a morphological hallmark of sprouting angiogenesis 
(Fig. 4 E). Sox17-deficient vessels exhibited a more severe defi-
ciency of pericytes, basement membrane, and junctional VE-cad-
herin than control HGG vessels (Fig. 4, F and G; and Fig. S2 I). 
The severity of hypoperfusion, leakage, and microhemorrhage 
was increased in Sox17-deficient vessels compared with control 
HGG vessels (Fig. 4, H and I; and Fig. S2 J). Concomitantly, Sox17 
deletion increased tumor hypoxia (Fig. 4  J). In contrast, Sox17 
deletion induced no noticeable vessel changes in nontumor brain 
tissues (Fig. S3, H–M). These findings indicate that Sox17 deletion 
can promote tumor angiogenesis and aggravate morphological, 
structural, and functional abnormalities of HGG vessels. Notably, 
Sox17 deletion affected tumor progression, tumor vessels, and the 
oxygen environment in an opposite manner to Sox7 deletion.
We studied mechanisms of promoted tumor growth by Sox17 
deletion. Sox17 deletion promoted necrosis, apoptosis, and pro-
liferation (Fig. S2, K–M), which is unlikely to underlie acceler-
ated tumor growth. However, Sox17 deletion increased tumor 
infiltration into surrounding brain tissue (Fig. 4 K and Fig. S2 
N). In addition, intracranial metastasis was observed in mutant 
mice lacking endothelial Sox17, compared with no metastasis 
in controls (Fig. 4 L). These results suggest that Sox17 deletion 
exacerbates hypoxia-driven tumor invasion, thereby promot-
ing tumor growth.
Sox7 is up-regulated in HGG vessels via Dll4-induced Sox17 
down-regulation
Sox7 and Sox17 are opposing regulators and inversely expressed 
in HGG. We studied whether Sox7 and Sox17 can suppress the 
expression of one another in HGG vessels. Sox17-deficient vessels 
expressed Sox7 more abundantly (1.5-fold) than control HGG ves-
sels (Fig. 5 A). Sox7-deficient vessels expressed Sox17 at a com-
parable level with control HGG vessels (Fig. 5 B). However, Sox7 
or Sox17 deletion resulted in no discernable changes in Sox17 and 
Sox7 expression in nontumor brain vessels (Fig. S3, G and N). 
These findings indicate that Sox17 can inhibit Sox7 expression, 
but Sox7 does not repress Sox17 expression in HGG vessels.
We further studied whether increased Sox7 expression in 
Sox17-deficient HGG vessels is functionally important. Pheno-
types severely abnormal for tumor growth (Fig. 5 C), tumor ves-
sels (Fig. 5, D–H), and tumor hypoxia (Fig. 5 I) caused by Sox17 
deletion were significantly rescued by additional Sox7 deletion 
as shown by the attenuated abnormalities in mutant mice lack-
ing both Sox7 and Sox17, suggesting Sox7 up-regulation as one of 
the mechanisms of tumor and vessel abnormalities enhanced by 
Sox17 deletion. These results also suggest a correlation in the level 
of Sox7 expression with the severity of HGG and HGG vessels.
Dll4 signaling inhibited Sox17 expression in tumor vessels 
in our previous study of a subcutaneous LLC tumor model (Lee 
et al., 2014). In contrast to the lack of detectable expression in 
normal brain vessels, Dll4 expression was substantial in HGG 
vessels, but it was merely modest in other cells (Fig. 6 A). We 
explored whether Dll4 signaling can down-regulate Sox17 in 
HGG vessels by excising endothelial Dll4. Dll4 deletion reduced 
tumor growth and affected HGG vessels, as shown by decreased 
vessel area and diameter (Fig. 6, B–E). Dll4-deficient HGG ves-
sels expressed Sox17 at fourfold higher levels than control HGG 
vessels, but Sox7 was expressed at one-fourth the level of control 
HGG vessels (Fig. 6, F and G). We elucidated whether repressed 
Sox7 expression by Dll4 deletion was mediated by increased Sox17 
expression. α-Dll4 neutralizing Ab repressed Sox7 expression in 
control HGG vessels similar to genetic Dll4 ablation, but not in 
Sox17-deficient vessels (Fig. 6 H), indicating the need for Sox17 
(BM; G) and quantification of coverage. (H) Lectin and quantification of vascular perfusion. (I) Ter119-positive erythrocytes and quantification of hemorrhage. 
(J) Hypoxyprobe (HP) adduct and quantification of hypoxic area. (K) Enhanced perivascular invasion of GL261-GFP tumor cells by Sox17 deletion. (L) Enlarged 
images of boxed area in A showing intracranial metastasis in KO mice and its quantification. Values are presented as mean ± SD (n = 5 unless otherwise denoted). 
*, P < 0.05; **, P < 0.01; ***, P < 0.001. Bars: 2 mm (A); 50 µm (E); 100 µm (C, D, and F–L).
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in Sox7 repression. α-Dll4 Ab increased Sox17 expression in both 
control and Sox7-deficient HGG vessels (Fig. 6 I), indicating the 
independence of Sox17 up-regulation from Sox7. These results 
suggest a regulatory axis in which Dll4 is turned on in HGG ves-
sels, repressing Sox17 expression and subsequently up-regulat-
ing Sox7, which is crucial for tumor vessel abnormalization.
Figure 5. Sox7 up-regulation is responsible for further vascular abnormality in Sox17-deficient HGG vessels. (A and B) Sox7 (A) and Sox17 (B) immunostain-
ing and quantification in HGG vessels of control, Sox7iΔEC (S7KO), or Sox17iΔEC (S17KO) mice. (C) GL261-GFP HGGs grown in control, S17KO, and Sox7/17iΔEC (DKO) mice 
and quantification of tumor volume (n = 10). (D–I) CD31-positive HGG vessels in control, S17KO, and DKO mice. (D) Vascular network and quantification of vessel 
area. (E and F) PDG FRβ-positive pericytes (E) and Col4-positive basement membrane (BM; F) and quantification of coverage. (G) Lectin and quantification of vascular 
perfusion. (H) Ter119-positive erythrocytes and quantification of hemorrhage. (I) GLUT1 immunostaining and quantification of hypoxic area. Values are presented as 
mean ± SD (n = 5 unless otherwise denoted). **, P < 0.01 versus control; ##, P < 0.01 versus Sox17iΔEC. NS, not significant. Bars: 100 µm (A, B, and D–I); 2 mm (C).
Kim et al. 
Sox7 abnormalizes high-grade glioma vessels
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20170123
971
Because a previous study identified Sox17 as a stimulator of 
Dll4 expression in arterial differentiation (Corada et al., 2013), 
we examined Dll4 expression in Sox7- and Sox17-deficient HGG 
vessels. Dll4 was not changed in Sox7-deficient vessels but was 
increased in Sox17-deficient vessels (Fig. 6  J), suggesting that, 
unlike arterial differentiation, Sox7 and Sox17 are not upstream 
of Dll4 in HGG. Increased hypoxia by Sox17 deletion may enhance 
Dll4 expression in tumor vessels (Patel et al., 2005).
VEG FR2 inhibition induces a variable tumor response based on 
Sox7 levels in tumor vessels
To understand the molecular characteristics of  Sox7- and 
Sox17-deficient tECs, we correlated their gene expression pro-
files. Between Sox7-deficient and control tECs, 2,165 genes 
were differentially expressed using twofold criteria, including 
down-regulation of Sox7 transcripts (log2fold change = −5.28). 
Gene set enrichment analysis using the GSEA tool with 2,165 
genes identified four gene sets with significant differences: 
angiogenesis and Wnt–β-catenin pathway (both enriched in 
control tECs) and DNA repair and allograft rejection (both 
enriched in Sox7-deficient tECs; Fig. 7 A). These data suggest 
that Sox7-deficient tECs are less angiogenic, more resistant 
to DNA damage stress, and more greatly associated with T 
cell–mediated immunity. Between Sox17-deficient and con-
trol tECs, 1,756 genes were differentially expressed, includ-
ing down-regulation of Sox17 transcripts (log2fold change = 
−7.25). Significant differences were identified in glycolysis 
and cell cycle progression signature gene sets, including MYC 
targets, E2F targets, and G2M checkpoint (Fig. 7 B), suggest-
ing altered cellular metabolism and proliferating capacity in 
Sox17-deficient tECs.
Given the fundamental role of VEGF signaling in tumor ves-
sels, we examined VEG FR2 expression in Sox7- and Sox17-defi-
cient HGG vessels. Compared with controls, VEG FR2 expression 
was repressed in Sox7-deficient vessels but was up-regulated in 
Sox17-deficient vessels (Fig. 7, C and D), indicating that Sox7 pro-
motes and Sox17 represses VEG FR2 expression in HGG vessels. 
In addition, Sox17-deficient vessels showed increased levels of 
phosphor-VEG FR2 (at Tyr1175), phosphor-ERK (at Thr202 and 
Tyr204 of ERK1 and Thr185 and Tyr187 of ERK2), and phos-
phor-Akt (at Ser473), reflecting functionally activated VEG FR2 
signaling by Sox17 deletion (Fig. 7, E–G).
To determine whether VEG FR2 up-regulation is responsi-
ble for increased vessel abnormality, we administered DC101, 
α-VEG FR2 blocking Ab, or control Ab to Sox17iΔEC mice bearing 
orthotopic HGG. Compared with control Ab, DC101 administra-
tion decreased tumor size to the size of tumors grown in con-
trol mice (Fig. 8, A and G) and significantly extended the sur-
vival of HGG-bearing Sox17iΔEC mice (median survival: 28 d on 
DC101 treatment vs. 24 d on control Ab; Fig. 8 H). DC101, but not 
control Ab, attenuated the abnormality of Sox17-deficient ves-
sels by decreasing vascular area and sprouts (Fig. 8, B, I, and J) 
and restoring basement membrane to the extent of control HGG 
vessels (Fig.  8, C and K). DC101 also diminished microhemor-
rhage, hypoxia, and invasion within tumors grown in Sox17iΔEC 
mice to the level of tumors grown in control mice (Fig. 8, D–F 
and L–N). These results suggest that VEG FR2 up-regulation is a 
key mechanism underlying overall adverse changes induced by 
Sox17 deletion.
We examined the effect of VEG FR2 inhibition in control mice 
with moderate VEG FR2 expression in HGG vessels. Compared 
with control Ab, DC101 suppressed tumor growth (Fig. 8, A and 
G) and induced a modest survival benefit (median survival: 29.5 
d on DC101 treatment vs. 27.5 d on control Ab; Fig. 8 H). DC101 
also suppressed area, sprouts, and basement membrane cover-
age of control HGG vessels compared with control Ab (Fig. 8, B, 
C, and I–K), featuring vessel regression. In line with this, DC101 
increased hypoxia and invasion within tumors grown in control 
mice (Fig.  8, E, F, M, and N). Phenotypes induced by VEG FR2 
inhibition in control mice were consistent with a previous study 
(Pàez-Ribes et al., 2009) showing that VEGF signaling block-
ade inhibits tumor growth transiently but triggers a resistant 
response to severe hypoxia.
Because VEG FR2 expression was remarkably lower in 
Sox7-deficient vessels compared with control HGG vessels, we 
studied whether VEG FR2 blockade is also able to inhibit tumor 
growth in Sox7iΔEC mice. In contrast to control and Sox17iΔEC 
mice, DC101 increased tumor growth in Sox7iΔEC mice (Fig. 8, A 
and G) and shortened the survival of HGG-bearing Sox7iΔEC mice 
(median survival: 31.5 d on DC101 treatment vs. 33.5 d on control 
Ab; Fig. 8 H). DC101 decreased the area and basement membrane 
in Sox7-deicient vessels (Fig. 8, B, C, and I–K). DC101 aggravated 
microhemorrhage and hypoxia in tumor tissues and promoted 
tumor invasion in Sox7iΔEC mice (Fig.  8, D–F and L–N). These 
findings indicate that VEG FR2 inhibition can adversely affect 
tumor progression by inducing severe vascular rarefaction in 
the Sox7-deficient context and suggest that low levels of Sox7 
and VEG FR2 may be associated with poor outcomes after VEG 
FR2 blockade in the treatment of HGG.
Sox7 deletion inhibits HGG by boosting T cell–
mediated tumor immunity
Because impaired T cell immunity is central to immune suppres-
sion in cancers, we assessed the abundance of CD4+ helper T cells, 
CD8+ cytotoxic T cells, and FoxP3+ regulatory T cells (T reg cells) 
in HGG grown in Sox7iΔEC and Sox17iΔEC mice. Compared with 
control, Sox7 deletion increased CD8+ T cells and decreased T reg 
cells, whereas Sox17 deletion increased T reg cells (Fig. 9, A–D). 
The frequency of CD4+ T cells was not changed (Fig. 9, A and B). 
In contrast to HGG, T reg cells were very rare in normal brain tis-
sue (Fig. 9 E). Considering that T reg cells suppress the cytotoxic 
function of CD8+ T cells (Nishikawa and Sakaguchi, 2014), these 
findings suggest that Sox7 deletion enhances T cell–mediated 
immunity, but Sox17 deletion inhibits it by regulating T reg cell 
abundance specifically in HGG tissues.
To understand the underlying mechanisms, we measured the 
tumoral concentration of CCL17, CCL22, and CCL5, well-known 
chemokines for T reg cell recruitment (Curiel et al., 2004; 
Mizukami et al., 2008; Schlecker et al., 2012). Sox7 deletion 
reduced the concentration of CCL17, CCL22, and CCL5, whereas 
Sox17 deletion increased the CCL17 concentration (Fig. 9 F). These 
results suggest that Sox7 and Sox17 regulate CCL5/17/22-medi-
ated T reg cell recruitment into tumor tissues, leading to immune 
control of HGG growth.
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Figure 6. Dll4 increases Sox7 expression in HGG vessels via Sox17 down-regulation. (A) Dll4 immunostaining in nontumor brain and HGG vessels. 
(B) GL261-GFP HGGs grown in control (Ctrl) and Dll4iΔEC (Dll4KO) mice and quantification of tumor volume. (C-E) CD31-positive HGG vessels in control and 
Dll4KO mice (C) and quantification of vessel area (D) and diameter (E). (F and G) Sox7 (F) and Sox17 (G) immunostaining and quantification in HGG vessels of 
control and Dll4KO mice. (H and I) Sox7 (H) and Sox17 (I) immunostaining and quantification in HGG vessels of control, Sox7iΔEC (S7KO), or Sox17iΔEC (S17KO) 
mice administered control (IgG) or α-Dll4 Ab. (J) Dll4 immunostaining and quantification in HGG vessels from control, Sox7iΔEC, and Sox17iΔEC mice. Values are 
presented as mean ± SD (n = 5). *, P < 0.05; **, P < 0.01 versus control; #, P < 0.05 versus Sox17iΔEC. NS, not significant. Bars, 100 µm.
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Sox7 expression in tumor vessels is associated with poor 
prognosis and impaired vasculature in grade IV glioma patients
We studied the clinical relevance of Sox7 in HGG. Grade IV glioma 
patients were divided into two groups based on Sox7 expression 
in tumor vessels, implying endothelial heterogeneity in HGG. 
Among 189 patients, Sox7 was detectable in the tumor vessels 
of 62 Sox7-positive patients (Fig. 10 A). Of the 127 Sox7-negative 
patients, 71% expressed a high level of Sox17 in tumor vessels, 
but only 23% of Sox7-positive patients expressed Sox17 at a high 
level (Fig. 10 A), indicating an inverse relationship between Sox7 
and Sox17 expression. Compared with Sox17-high tumor ves-
sels, Sox7-positive tumor vessels were small and well branched 
(Fig. 10 B). Overall survival and progression-free survival were 
significantly poorer in the Sox7-positive population compared 
with the Sox7-negative population (Fig.  10, C and D; and Fig. 
S4 A). In contrast, when patients were divided based on Sox17 
expression in tumor vessels, the Sox17-high and Sox17-low 
patient populations exhibited no difference in overall and pro-
gression-free survival (Fig. S4, B and C).
Patient groups with Sox7-positive tumor vessels exhibited 
poorer symptoms and a higher degree of peritumoral edema 
in the circumferential region at diagnosis compared with the 
other group (Fig. S4, D and E), suggesting more vessel leakage 
in the Sox7-positive population. Consistently, the Sox7-positive 
patients tended to have abundant hemorrhage in specimens 
relative to Sox7-negative patients (Fig. 10, E and I). Dynamic 
Figure 7. Sox7 up-regulates and Sox17 down-regulates VEG FR2 in HGG vessels. (A and B) GSEA of differentially expressed genes in Sox7-deficient (A) and 
Sox17-deficient (B) tECs compared with controls according to RNA sequencing. FDR, false discovery rate; NES, normalized enrichment score. (C–G) CD31-pos-
itive HGG vessels. (C) Repressed VEG FR2 in Sox7iΔEC (S7KO) mice. (D–G) Enhanced VEG FR2 (D), phosphor (p)-VEG FR2 (E), p-ERK (F), and p-Akt (G) in Sox17iΔEC 
(S17KO) mice. Values are presented as mean ± SD (n = 5). **, P < 0.01. Bars, 100 µm.
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contrast-enhance (DCE) magnetic resonance (MR) imaging and 
accompanying flow decay mapping also showed more intratu-
moral leakage and peritumoral edema in Sox7-positve patients 
relative to Sox7-negative patients (Fig.  10, F, H, J, and L; and 
Fig. S4 F). On perfusion MR imaging, Sox7-positive patients had 
prominent blood flow within the tumor relative to Sox7-nega-
tive patients (Fig. 10, G and K; and Fig. S4 G), implying more 
severe tumor malignancy and abnormally enhanced vessel 
area in Sox7-positive patients. These findings indicate that 
the Sox7-positive patients have more severely impaired intra-
tumoral vascular function than the others. Collectively, these 
clinical data based on a large HGG patient population reveal the 
heterogeneity of Sox7 expression, present Sox7 as a vascular 
marker of poor prognosis, and implicate Sox7 in tumor ves-
sel abnormality.
Discussion
In this study, we revealed that two homologous transcription 
factors, Sox7 and Sox17, broadly contrast across expression, 
function, and therapeutic response in orthotopic HGG models 
(Fig. S4 H). Activated Sox7 promotes vascular abnormalities, 
such as tumor angiogenesis, vessel destabilization, vasodilation, 
and impaired vascular function, subsequently leading to tumor 
hypoxia and tumor growth. In contrast, Sox17 in HGG vessels 
antagonizes these malignant changes. VEG FR2 inhibition delays 
tumor growth by normalizing Sox17-deficient vessels with high 
levels of Sox7 but promotes tumor growth by impairing Sox7-de-
ficient vessels. In the human HGG patient population, Sox7 is 
expressed in one-third of patients with poor clinical outcome 
and impaired tumor vascular function.
HGG is characterized by angiogenic vessels, and several pro-
cesses, such as sprouting, vascular differentiation from can-
cer stem cells, and vascular mimicry, have been suggested as 
potential angiogenic mechanisms (Jain et al., 2007; Wang et al., 
2010; Cheng et al., 2013; Das and Marsden, 2013). However, the 
precise mechanisms of its tumor angiogenesis remain elusive 
because vessel cooption, rather than angiogenesis, is the main 
vessel characteristic of animal HGG models (Blouw et al., 2003; 
Bergers and Hanahan, 2008; Du et al., 2008). The general mech-
anism of tumor angiogenesis has been established based on 
angiogenic tumor models, such as spontaneous pancreatic islet 
tumors, orthotopic breast tumors, and subcutaneous ectopic 
tumors (Carmeliet and Jain, 2011; Hanahan and Weinberg, 2011; 
Saharinen et al., 2011). The limited benefit of antiangiogenic 
therapy in HGG patients may be ascribed to the lack of knowledge 
on HGG angiogenesis.
We found that sprouting angiogenesis is inactive in intracra-
nial HGG grown in wild-type mice. However, endothelial Sox17 
deletion activated tumor angiogenesis as shown by abundant 
vascular sprouts and tip cells, indicating that Sox17 masks an 
angiogenic activity in HGG. In contrast, Sox17 promotes tumor 
angiogenesis in subcutaneous ectopic tumors (Yang et al., 2013). 
Regardless of the type of tumor cells, GL261- and LLC-derived 
tumors grown in a subcutaneous region exhibit strong Sox17 
expression, but the same tumors grown in the brain express 
Sox17 only modestly. Similarly, transcription factor HIF-1α–defi-
cient HGG cells elicit different vessel changes depending on the 
implantation site, being better vascularized when transplanted 
intracranially and poorly vascularized in subcutaneous environ-
ment (Blouw et al., 2003). These findings suggest that there is a 
mechanism of tumor angiogenesis specific to tumors grown in 
the brain. In contrast to their opposing expression and function 
in intracranial tumors, Sox7 and Sox17 exhibit overlap in expres-
sion and function and jointly promote developmental angio-
genesis in the postnatal brain (Kim et al., 2016). These findings 
suggest that Sox7 and Sox17 can choose different relationships 
even in the same brain region depending on the vascular context. 
Likewise, homologous transcription factors Irx3 and Irx5 have 
a cooperative role in embryonic cardiac morphogenesis but an 
antagonistic role in postnatal cardiac conduction (Gaborit et al., 
2012). Together, the tumor as a pathological factor and the brain 
as a regional factor set the opposing expression and function of 
Sox7 and Sox17 for HGG angiogenesis.
Contrasting Sox7 and Sox17 expression in HGG vessels is 
sculpted by Dll4 signaling and their epistatic regulation; Dll4 
repressed Sox17 expression and Sox17 repressed Sox7 expres-
sion in tECs. Thus, Dll4 up-regulation promotes the expression 
of proangiogenic factor Sox7 via Sox17 repression. Consistently, 
Dll4 deletion decreased vascular area in intracranial HGG. On 
the contrary, Dll4 blocking is known to promote nonproductive 
tumor angiogenesis in subcutaneous tumor models via unknown 
mechanisms (Noguera-Troise et al., 2006; Ridgway et al., 2006), 
suggesting that Dll4 signaling regulates tumor angiogenesis dif-
ferently depending on the tumor type. The regulatory cascade 
in tECs continues to VEG FR2; Sox7 promoted VEG FR2 expres-
sion, but Sox17 repressed it. In general, VEG FR2 is fundamental 
for vessel abnormalities in various tumors (Carmeliet and Jain, 
2011; Saharinen et al., 2011). VEG FR2 levels in tumor vessels also 
correlated with vessel abnormality, hypoxia, and tumor growth 
in HGG models. Importantly, tumor angiogenesis, vessel desta-
bilization, and tumor growth promoted by Sox17 deletion were 
rescued by either Sox7 deletion or VEG FR2 inhibition, verify-
ing their functional relationship. Our study established that the 
Figure 8. Vascular and tumor responses to VEG FR2 inhibition are variable according to Sox7 levels in HGG vessels. Control (Ctrl), Sox7iΔEC (S7KO), and 
Sox17iΔEC (S17KO) mice bearing HGG were administered with control (IgG) or α-VEG FR2 (DC101) Ab. (A) GL261-GFP HGGs. (B–F) CD31-positive HGG vessels. (B) 
Vascular network. (C) Col4-positive basement membrane (BM). (D) Ter119-positive erythrocytes. (E) GLUT1 immunostaining. (F) Invasion of GL261-GFP tumor 
cells at the tumor periphery. (G) Quantification of tumor volume in A. (H) Survival curves for HGG-bearing mice (n = 8). (I and J) Quantification of vessel area 
(I) and sprouts (J) in B. (K) Quantification of coverage in C. (L) Quantification of hemorrhage in D. (M) Quantification of hypoxic area in E. (N) Quantification 
of perivascular invasion in F. Values are presented as mean ± SD (n = 5 unless otherwise denoted). *, P < 0.05; **, P < 0.01; ***, P < 0.001 versus control/IgG; 
#, P < 0.05; ###, P < 0.001 versus Sox7iΔEC/IgG; $, P < 0.05; $$, P < 0.01; $$$, P < 0.001 versus Sox17iΔEC/IgG (log-rank test). NS, not significant. Bars: 2 mm 
(A); 100 µm (B–F).
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Figure 9. Sox7  deletion inhibits tumor infil-
tration of T reg cells, whereas Sox17 deletion 
increases it. (A–D) FACS plots and frequency of 
CD4+ and CD8+ T cells (A and B) and T reg cells 
(CD45.2+ CD11b− CD4+ CD8− FoxP3+; C and D) in 
HGG grown in control (Ctrl), Sox7iΔEC (Sox7KO), and 
Sox17iΔEC (Sox17KO) mice (n = 6). (E) Negligible T reg 
cell frequency in nontumor brain tissues. (F) ELI SA 
analysis of CCL5, CCL17, and CCL22 in HGG. Data 
are presented as mean ± SD (n = 4 unless otherwise 
denoted). *, P < 0.05; **, P < 0.01.
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Sox7–VEG FR2 axis drives tumor angiogenesis, vessel abnormal-
ization, and tumor growth in HGG, and Sox17 antagonizes these 
processes by repressing Sox7 expression.
Immune suppression is a key process for tumor growth, and T 
reg cells inhibit T cell–mediated immunity in a range of tumors 
(Nishikawa and Sakaguchi, 2014). T reg cells were also abundant 
in our HGG models. Importantly, Sox7 deletion decreased the T 
reg cell frequency and delayed tumor growth, whereas Sox17 dele-
tion increased T reg cell abundance and promoted tumor growth, 
suggesting that Sox7 and Sox17 control tumor progression in part 
via T reg cells. Several studies have reported that hypoxia and 
glucose shortage can exacerbate immune suppression in tumors 
(Clambey et al., 2012; Barsoum et al., 2014). Enhanced oxygen and 
glucose supply by Sox7-deficient vessels may foster a tumor envi-
ronment favorable for T cell–mediated immunity.
Sox7 and Sox17 induce opposing responses to VEG FR2 inhibi-
tion. Regarding the absence or presence of therapeutic outcome 
of antiangiogenic therapy, HGG patients can be categorized into 
two groups: the nonresponder, which is intrinsically refractory 
to therapy, and the responder (Batchelor et al., 2007; Chinot et 
al., 2014; Gilbert et al., 2014). However, in several studies based 
on animal models, anti-VEGF therapies induce a single pat-
tern of response in HGG rather than dichotomy; it transiently 
delays tumor growth but soon induces adaptive resistance, such 
as enhanced tumor invasiveness, leading to tumor recurrence 
(Batchelor et al., 2007; Bergers and Hanahan, 2008; Lu et al., 
2012; Scholz et al., 2016). Thus, how antiangiogenic therapy 
can elicit different therapeutic outcomes remains unknown. In 
this study, α-VEG FR2 Ab produces three different patterns of 
response in survival and resistant glioma invasion: increased 
survival with proinvasive adaptation in the control, decreased 
survival with aggressively enhanced invasion in the group lack-
ing endothelial Sox7, and increased survival with less invasion 
in the group lacking endothelial Sox17. Whereas α-VEG FR2 Ab 
induces rarefaction of Sox7-deficient HGG vessels with less 
abnormality, it stabilizes Sox17-deficient HGG vessels with 
aberrant angiogenesis and severe abnormality. These vessel 
changes subsequently affect tumor hypoxia and, finally, tumor 
invasiveness. Interestingly, this hypoxic-driven tumor invasion 
is often observed in the vessel cooption mediating resistance 
to anti-VEGF therapy in several tumor contexts such as HGG 
and liver metastases (Lu et al., 2012; Frentzas et al., 2016). In 
our HGG models, VEG FR2 blocking decreased endothelial Dll4 
expression (Fig. S5 D), which can subsequently induce several 
vessel changes, including Sox7 and Sox17 expression. Further 
studies will reveal detailed molecular mechanisms for the het-
erogeneous response to α-VEG FR2 Ab. Our findings suggest 
that variable vascular and tumor responses to α-VEG FR2 Ab are 
attributed to heterogeneous vessel abnormality, which is regu-
lated by Sox7 and Sox17.
Our findings suggest that a small subset hidden in the nonre-
sponder group may have an immediate adverse outcome, rather 
than indifference, to α-VEG FR2 Ab, suggesting that the range of 
heterogeneity in therapeutic response to antiangiogenic ther-
apy may be wider than currently thought. However, anti-VEGF 
therapy could give a better clinical outcome such as significantly 
enhanced overall survival to a subpopulation, which in particu-
lar has a severe vascular abnormality. In this regard, predictive 
biomarkers, which are now missing, may improve the efficacy 
of anti-VEGF therapy by selecting suitable patient group. In con-
trast to transient vessel normalization by antiangiogenic therapy 
(Jain et al., 2007; Saharinen et al., 2011; Van der Veldt et al., 2012), 
α-VEG FR2 Ab induces enduring normalization in Sox17-deficient 
HGG vessels, suggesting its combination with chemotherapy 
for additional therapeutic benefit. Our study also suggests that 
ramucirumab, an α-VEG FR2 Ab approved for the treatment of 
gastric cancer and non–small cell lung cancer (Fuchs et al., 2014; 
Garon et al., 2014; Wilke et al., 2014), is suitable for indication 
expansion to HGG because it effectively delays tumor growth by 
normalizing tumor vessels in a certain tumor context.
Importantly, we verified clinical relevance of Sox7 in HGG 
patients. Although HGG is divided into subtypes based on histo-
pathologic and molecular analysis (Verhaak et al., 2010; Brennan 
et al., 2013), its vascular pattern remains entangled as a result 
of its high degree of heterogeneity. We divided HGG patients on 
the immunohistologic basis of Sox7 expression in tumor vessels. 
High Sox7 levels correlated with hyper-leakage and predicted 
poor prognosis of patients. These results suggest that Sox7 pro-
motes vessel abnormality and, consequently, tumor growth in 
HGG patients. Similar to mouse HGG models, the expression of 
Sox7 and Sox17 exhibited an inverse relationship in specimens 
from HGG patients. However, Sox17 levels are independent from 
prognosis of patients. A future study will elucidate the role of 
Sox17 in total HGG consisting of various subtypes. Given only a 
few prognostic markers available for HGG, such as methylation 
of methylguanine methyltransferase promoter (Hegi et al., 2005) 
and IDH1 mutation (Yan et al., 2009) on the basis of tumor het-
erogeneity, our findings provide an insight into an alternative 
option for prognostic markers based on endothelial heterogene-
ity. Though endothelial Sox7 was detected in one-third of HGG 
patients, we found nonendothelial Sox7 expression in some 
human HGG sections. As a result of a wide range of intra- and 
intertumoral heterogeneities, we were not able to characterize 
the pattern of nonendothelial Sox7 expression in human HGG. 
Figure 10. Sox7 expression in tumor vessels correlates with poor prognosis and impaired tumor vessels of grade IV glioma patients. (A) Categorization 
of grade IV glioma patients based on Sox7 levels in tumor vessels. (B) Immunostaining for Sox7 and Sox17. (C and D) Overall survival (C) and progression-free 
survival (D) of Sox7-positive (n = 62) and Sox7-negative (n = 127) patients. *, P < 0.05; **, P < 0.01 (log-rank test). (E–L) Representative images of Sox7-negative 
(E–H) and Sox7-positive (I–L) patients. (E and I) H&E images (left). Enlarged images of boxed area (right). (F and J) DCE MR images (left) and enlarged views of 
red-lined box (right). (G and K) Perfusion MR images (left) and enlarged views of red lined box (right). Insets are regions for measuring flow decay. Color index 
denotes the intensity of blood flow signal. Red dotted lines: tumor margin. Blue dotted lines: peritumoral edema margin. Asterisk denotes copious peritumoral 
leakage. (H and L) Negative integral map showing blood flow decay at multiple regions. Each line denotes the dynamic flow signal from single inset in G and K 
(right). Delayed signal recovery indicates vessel leakage caused by poor removal of extravasated gadolinium. See Fig. S4 (F and G) for quantitation of intratu-
moral leakage (F, H, J, and L) and tumor perfusion (G and K), respectively. Bars: 100 µm (B, E [right], and I [right]); 200 µm (E, left; I, left).
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Further investigation based on advanced models will elucidate 
additional roles of Sox7 in HGG.
In summary, Sox7 promotes tumor angiogenesis in HGG by 
up-regulating VEG FR2. HGG exhibits a variable therapeutic 
response to α-VEG FR2 Ab depending on Sox7 level in tumor ves-
sels. For clinical relevance, high Sox7 levels predict poor survival, 
early recurrence, and impaired tumor vascular function in HGG 
patients. Our study identifies a novel proangiogenic factor Sox7 
for HGG and proposes that Sox7 might have potential as a predic-
tive biomarker for antiangiogenic therapy.
Materials and methods
Study design
The overall objective of this controlled laboratory experimen-
tal study was to investigate the role of Sox7 and Sox17 in mouse 
HGG models. We used targeted mouse models with intracra-
nially implanted glioma cells. We treated tumor-bearing mice 
with α-VEG FR2 Ab to evaluate therapeutic outcome to antian-
giogenic treatment. Vascular morphology, leakage, perfusion, 
and hypoxia were assessed by confocal microscopy. Sample size 
was determined by the statistical software PASS 12 (power anal-
ysis and sample size) using the preliminary dataset to detect a 
difference in means between experimental and control groups. 
No special but general randomized determination was used for 
animal allocation. All data were included, and investigators were 
not blinded for the animal study. All animal experiments were 
approved by the Animal Care Committee of Korea Advanced 
Institute of Science and Technology (KA2013-41). In addition, 
a retrospective cohort of HGG patients was evaluated for Sox7 
and Sox17 expression under approval by the Institutional Review 
Board of Asan Medical Center (2011-1012). The grade IV glioma 
patients with the standard therapy were enrolled in this study 
by excluding patients with palliative treatments. Correlation of 
Sox7 and Sox17 levels with prognosis and vascular function of 
patients was evaluated.
Tumor models and treatment regimens
The murine GL261 glioma line was obtained from K. Plate 
(Goethe University Medical School, Frankfurt, Germany). The 
GL261-GFP glioma cell line was generated by transducing GL261 
cells with lentivirus carrying GFP-expressing vector. LLC cells 
were obtained from the American Type Culture Collection. 
83NS patient-derived glioblastoma stem cells were maintained 
as described previously (Yin et al., 2017). No mycoplasma was 
detected in the cell cultures. For intracranial tumor models, 2 × 
105 GL261, 2 × 105 GL261-GFP, 2 × 105 LLC cells, and 5 × 105 83NS 
cells were implanted into the right hemispheres of 8–10-wk-old 
male experimental mice via stereotaxic injection. For subcuta-
neous tumor models, suspensions of GL261 or LLC (106 cells in 
100  µl) were subcutaneously injected into the dorsal flank of 
8–10-wk-old male experimental mice. Littermates were used 
in all experiments. We generated the constructs for α-Dll4 Ab 
based on the sequence of the variable regions of clone 26.82 (US 
7803377 B2) and validated its efficacy via excessive postnatal 
retina angiogenesis (Fig. S5 A). We also validated the efficacy of 
α-VEG FR2 Ab (DC101) by inhibited postnatal retina angiogenesis 
(Fig. S5 B). To block Dll4 and VEG FR2, 5 mg/kg α-Dll4 Ab, 40 mg/
kg DC101, or an equal amount of their control Abs was injected 
into tumor-bearing mice (Fig. S5 C). To measure tumor vol-
ume, at least eight coronal brain sections were prepared every 
100 µm, placing bregma in the center section. Among the eight 
brain slices, the section with the largest tumor was selected, and 
tumor volume was calculated according to the formula 0.5 × A × 
B2, where A is the longest diameter of a tumor, and B is its per-
pendicular diameter.
Statistical analysis
Experimental values are presented as mean ± SD unless other-
wise indicated. Significance was determined by the Mann-Whit-
ney U test between two groups or the Kruskal-Wallis test followed 
by the Tukey’s HSD (honest significant difference) test with 
ranks for more than three groups. Survival curves were evalu-
ated using the Kaplan-Meier method, and statistical differences 
were determined using the log-rank test. Statistical analyses 
were performed using PASW statistics 18 (SPSS). P < 0.05 was 
considered significant.
Mice
The Cdh5(BAC)-CreERT2 model was obtained from Y. Kubota (Keio 
University, Tokyo, Japan). Sox7mCh/+ (Kim et al., 2016), Sox7fl/+ 
(Kim et al., 2016), Sox17GFP/+ (Kim et al., 2007), Sox17fl/+ (Kim et 
al., 2007), Dll4fl/+ (Hozumi et al., 2008), and Cdh5(BAC)-CreERT2 
(Okabe et al., 2014) mice were housed in a pathogen-free animal 
facility. All mouse lines were backcrossed onto the C57BL/6 back-
ground at least 10 times. To excise Sox7, Sox17, and Dll4 in ECs, the 
Cdh5(BAC)-CreERT2 driver line was bred with Sox7fl/fl, Sox17ffl/fl, 
and Dll4fl/fl mice, and experimental mice were intraperitoneally 
administered 20 mg/kg tamoxifen (Sigma). Mice were anesthe-
tized with 80 mg/kg ketamine and 12 mg/kg xylazine, and their 
brains were harvested for further analyses. All animal experi-
ments were approved by the Animal Care Committee of Korea 
Advanced Institute of Science and Technology (KA2013-41).
Histological analyses
For H&E staining, tumors and indicated organs were fixed over-
night in 4% paraformaldehyde (PFA), embedded in paraffin, and 
cut into 3-µm sections. For immunofluorescence, samples were 
fixed in 1% PFA, dehydrated in 20% sucrose solution overnight, 
and embedded in tissue-freezing medium (Leica). Frozen blocks 
were cut into 30-µm sections. Tissue sections were blocked in 
PBST (0.3% Triton X-100 in PBS) with 5% goat or donkey serum 
and incubated with the following primary Abs: α–mouse CD31 
(hamster [2H8; Millipore] or rat [MEC13.3; BD Biosciences]), α–
human CD31 (rabbit polyclonal; Abcam), α-Sox7 (goat; R&D Sys-
tems), α-Sox17 (goat; R&D Systems), α-PDG FRβ (rat; clone APB5; 
eBioscience), α–collagen type IV (rabbit; Cosmo Bio), α-Ter119 
(rat; eBioscience), α-GLUT1 (rabbit; Millipore), α-VEG FR2 (goat; 
R&D Systems), α-ZO-1 (rabbit; Invitrogen), α–VE-cadherin (rat; 
BioLegend), α-PH3 (rabbit; Millipore), α-Caspase3 (rabbit; Mil-
lipore), α–phospho-VEG FR2 (rabbit; Cell Signaling), α–phos-
pho-ERK (rabbit; Cell Signaling), or α–phospho-Akt (rabbit; Cell 
Signaling). After several washes, sections were incubated with 
the following secondary Abs: Alexa Fluor 488–, Alexa Fluor 596–, 
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or Alexa Fluor 647–conjugated α–hamster IgG, Alexa Fluor 488– 
or Alexa Fluor 596–conjugated α–rabbit IgG, Alexa Fluor 488– or 
Alexa Fluor 596–conjugated α–rat IgG (Jackson ImmunoRe-
search), or Alexa Fluor 488– or Alexa Fluor 596–conjugated α–
goat IgG (all Jackson ImmunoResearch). Nuclei were stained with 
DAPI (Invitrogen). The samples were then mounted with fluores-
cent mounting medium (DAKO), and immunofluorescent images 
were obtained using confocal microscope (LSM780; Zeiss).
Assessment of vascular leakage, perfusion, and hypoxia
To analyze vascular leakage, 8 ml/kg Evans blue solution (0.5%; 
Sigma) was injected intravenously 24 h before brains were har-
vested. To analyze vascular perfusion, 0.1 mg DyLight 488–con-
jugated tomato lectin (Vector Laboratory) was injected intra-
venously 30 min before brains were harvested. To detect the 
tumor hypoxic area, 60 mg/kg pimonidazole hydrochloride 
(Natural Pharmacia International) was injected intraperitone-
ally 60 min before brains were harvested. Mice were anesthe-
tized and perfused by intracardiac injection of 1% PFA to remove 
circulating Evans blue, lectin, and pimonidazole. Tumors were 
then harvested, sectioned, and stained with FITC-conjugated 
antihypoxyprobe Ab.
Morphometric and densitometric analyses
Vessel area was calculated as the CD31-positive area per random 
0.54-mm2 regions. The number of vessels and vascular branches 
were counted in random 0.54-mm2 regions. Vessel diameter and 
the number of vascular sprouts (>10 µm in length) were mea-
sured in random 0.13-mm2 regions. Vascular tortuosity was cal-
culated as described previously (Scott et al., 2014). Expression 
levels of Sox7, Sox17, Sox7-mCherry, Sox17-GFP, Dll4, and VEG 
FR2 were determined as percentages of the corresponding flu-
orescent-positive area per CD31-positive blood vessel. Coverage 
of PDG FRβ-positive pericyte, collagen type IV–positive basement 
membrane, and VE-cadherin–positive adherens junctions were 
calculated as the percentages of corresponding fluorescent-posi-
tive length along the CD31-positive blood vessels in random 0.54-
mm2 regions. Vascular perfusion was quantified as the percent-
age of FITC-lectin–positive area divided by CD31-positive area 
per random 0.54-mm2 regions. Hemorrhage, vascular leakage, 
hypoxic area, and apoptotic area were quantified as the percent-
ages of Ter119-, Evans blue–, GLUT1-, and caspase 3–positive 
area, respectively, per random 0.54-mm2 regions. The densities 
of immunofluorescence signals were quantified using ImageJ 
software (National Institutes of Health).
Flow cytometry
We performed flow cytometric analysis as described previously 
(Oh et al., 2017a). In brief, single cells were pretreated with 
α-CD16/32 Ab (2.4 G; TON BO Bioscience) and stained with the 
following Abs: α–mouse Foxp3 (FJK-16s; eBioscience), α–mouse 
CD8α (53-6.7; BD Biosciences), α–mouse CD11b (M1/70; BD 
Biosciences), α–mouse CD4 (GK1.5; BioLegend), or α–mouse 
CD45.2 (104; TON BO Bioscience). For T reg cell staining, Foxp3 
was stained using the Foxp3/Transcription factor staining 
buffer set (eBioscience) according to the manufacturer’s pro-
tocol. The stained cells were analyzed by cell analyzers (LSR 
Fortessa or LSR II; BD Biosciences). All data were analyzed using 
FlowJo (TreeStar).
ELI SA
We assessed the protein levels of CCL5, CCL17, and CCL22 using 
previously described methods with slight modification (Oh et 
al., 2017b). In brief, brain hemispheres containing GL261 HGG 
were chopped into small pieces in PBS with protease inhibitor 
(Roche). Tissue samples were homogenized by an ultrasonic dis-
membrator. After the samples were centrifuged at 3,000 g for 15 
min at 4°C, the supernatants were collected and stored at −80°C. 
CCL5, CCL17, and CCL22 were measured using ELI SA kits (R&D 
Systems) according to the manufacturer’s protocol.
Sorting of tECs
GL261-derived HGGs were broken into small pieces, incubated in 
buffer containing 0.1% collagenase type 1A (Worthington) and 3 
U/ml DNase I (Worthington) for 50 min at 37°C, strained with a 
40-µm nylon mesh to remove cell clumps, and incubated in lysis 
buffer for 2 min to remove erythrocytes. Single-cell suspensions 
were incubated for 30 min with biotin-conjugated α-CD31 Ab (rat; 
390; Miltenyi), washed, and incubated for 20 min with α-biotin 
microbeads (Miltenyi). CD31-positive cells were enriched using an 
autoMACS Pro separator (Miltenyi). Enriched cells were further 
stained with the following Abs: PE-conjugated α–mouse CD31 (rat; 
MEC 13.3; BioLegend), APC-conjugated α–mouse CD45 (rat; 30-F11; 
BioLegend), and APC-conjugated α–mouse Ter119 (rat; BioLegend). 
To discriminate dead cells, cells were stained with DAPI (Sigma) 
and purified by a flow cytometer (FAC SAria II; BD Biosciences).
RNA sequencing and data analysis
For control and test RNA, the library was constructed using SEN 
SE mRNA-Seq Library Prep kit (Lexogen) according to the man-
ufacturer’s instructions. In brief, mRNA was isolated from 2 µg 
of total RNA by oligo-dT magnetic beads and hybridized with 
starter/stopper heterodimers containing Illumina-compatible 
linker sequences. Reverse transcription, ligation of newly syn-
thesized cDNA inserts to the stopper, and second strand synthesis 
were performed serially to generate the library. High-throughput 
sequencing was performed as paired-end 100 sequencing using a 
HiSeq 2000 sequencing system (Illumina).
RNA sequencing reads were mapped using the TopHat soft-
ware tool to obtain the alignment file, which was used to assem-
ble transcripts, estimate their abundance, and detect differen-
tial expression of genes or isoforms using cufflinks. Clustering 
and heat map construction were performed using Cluster and 
Treeview as described previously (Eisen et al., 1998). Gene ontol-
ogy and the ingenuity pathway analysis (QIA GEN) was performed 
for the prediction of biological and signaling changes. GSEA soft-
ware was used to identify the differences in expressed gene sets 
between study and control groups (Subramanian et al., 2005). 
We compared gene expression levels between Sox7-deficient 
tECs (n = 2) and controls (n = 2) and between Sox17-deficient 
tECs (n = 3) and controls (n = 3). Poorly expressed genes in both 
the study and control groups were filtered out using two crite-
ria: maximum read count <100 and median read count <10. Next, 
twofold up-regulated or down-regulated genes were selected as 
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differentially expressed genes. Thus, 2,165 (1,218 up-regulated 
and 947 down-regulated) and 1,756 (861 up-regulated and 895 
down-regulated) genes were differentially expressed in Sox7- 
and Sox17-deficient tECs, respectively. Raw data were uploaded 
to the Gene Expression Omnibus database of the National Center 
for Biotechnology Information (GSE90459 and GSE107530).
Patient enrollment and specimen collection
Among 440 patients diagnosed as grade IV glioma upon radio-
logical examination, 277 patients were confirmed pathologically 
as having primary glioblastoma. By excluding 88 patients with 
palliative treatments, 189 patients treated with the standard 
therapy (surgical removal and concurrent chemoradiation ther-
apy) were collected and reviewed in this study. All human studies 
were approved by the Institutional Review Board of Asan Medical 
Center (2011-1012), and all patient samples were collected with 
written informed consent.
DCE MR imaging
Imaging was performed on a 3.0-T MP25 Ingenia (Philips). For 
DCE perfusion MR imaging, three-dimensional gradient-echo 
data with 21 sections were obtained before, during, and after the 
administration of 0.1 mmol/kg gadoterate meglumine at a rate of 
4 ml/s. The dynamic acquisition was performed with a temporal 
resolution of 3.22 s, and contrast agent was administered after 
10 baseline dynamic acquisitions (total of 120 dynamic acquisi-
tions). The detailed imaging parameters for DCE perfusion MR 
imaging were as follows: 6.4/3.1; flip angle, 15°; field of view, 24 
cm; section thickness, 4 mm; gap, none; and matrix, 184 × 186. 
The total acquisition time for DCE MR imaging was 5 min and 
41  s. These procedural images were aimed to cover the entire 
tumor. Data processing was performed using a postprocessing 
workstation (Philips Medical Systems). Normalized signal inten-
sity was plotted against time for the corresponding normal brain 
on the contralateral side and the lesion. The plot lines represent 
the fitted curves derived using the first-pass PM (photon map-
ping) algorithm. The percent signal recovery was obtained to 
measure tumor vessel leakage (Chen et al., 2016).
Online supplemental material
Fig. S1 shows that Sox7 and Sox17 levels with an inverse relation-
ship categorize HGG vessels by morphology. Fig. S2 shows that 
Sox7 and Sox17 deletion induce opposite changes on HGG and its 
vessels. Fig. S3 shows that Sox7 and Sox17 deletion have no effect 
on nontumor brain vessels. Fig. S4 shows that Sox7 expression 
correlates with poor symptoms and a higher degree of tumor 
leakage of grade IV glioma patients. Fig. S5 depicts the validation 
of α-Dll4 and α-VEG FR2 Abs.
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